Skip to Content

Label Changes for:

Atacand HCT (Candesartan Cilexetil/Hydrodchlorothiazide) Tablets

April 2013

Changes have been made to the CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013



  • Atacand HCT is contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs.
  • Do not co-administer Aliskiren with Atacand HCT in patients with diabetes